Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III DE-117B eye drops in primary open-angle glaucoma or ocular hypertension (China)
CTR20243528Phase 3Active
- Sponsor
- Santen Pharmaceutical
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of omidenepag isopropyl in open-angle glaucoma (OAG), ocular hypertension, sponsored by Santen Pharmaceutical. Started Dec 2024; status: active.
02
Drugs
omidenepag isopropyl
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on CTR20243528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243528.